WallStSmart
HUMA

Humacyte Inc

NASDAQ: HUMA · HEALTHCARE · BIOTECHNOLOGY

$1.13
-4.14% today

Updated 2026-06-02

Market cap
$299.73M
P/E ratio
P/S ratio
148.67x
EPS (TTM)
$-0.63
Dividend yield
52W range
$1 – $3
Volume
6.8M

Humacyte Inc (HUMA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$6.19M$1.49M$1.26M$1.56M$0.00$0.00$2.04M
Revenue growth (YoY)-75.9%-15.3%+23.9%-100.0%
Cost of revenue$75.60M$54.08M$61.34M$8.26M$76.55M$7.19M$17.05M
Gross profit$-69.42M$-52.59M$-60.08M$-6.69M$-76.55M$-7.19M$-15.01M
Gross margin-1122.0%-3527.0%-4756.8%-427.5%-736.5%
R&D$75.60M$54.08M$61.34M$63.26M$76.55M$88.60M$69.30M
SG&A$16.27M$11.86M$21.02M$22.88M$23.39M$25.80M$31.17M
Operating income$-85.69M$-64.60M$-81.21M$-84.58M$-100.05M$-114.40M$-107.44M
Operating margin-1385.0%-4332.7%-6429.8%-5404.3%-5271.7%
EBITDA$-78.94M$-56.25M$-13.89M$2.44M$-96.46M$-132.23M$-22.24M
EBITDA margin-1275.9%-3772.6%-1099.6%156.2%-1091.2%
EBIT$-85.69M$-64.60M$-22.13M$-5.76M$-104.18M$-139.42M$-29.58M
Interest expense$2.30M$2.20M$4.35M$6.20M$6.60M$9.28M$11.25M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-85.42M$-66.52M$-26.48M$-11.96M$-110.78M$-148.70M$-40.83M
Net income growth (YoY)+22.1%+60.2%+54.8%-825.8%-34.2%+72.5%
Profit margin-1380.7%-4461.7%-2096.4%-764.5%-2003.6%

Frequently asked questions

What is Humacyte Inc's revenue?

Humacyte Inc's trailing twelve-month revenue is $2.02M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is HUMA?

In its most recent fiscal year, HUMA ran a gross margin of -736.46%, an operating margin of -5,271.69%, and a net margin of -2,003.58%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does HUMA generate?

HUMA produced $-105.93M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HUMA's balance sheet healthy?

HUMA holds $50.50M in cash and equivalents against $35.44M in long-term debt, on $3.11M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.